Tracer library / [111In]pb12
[111In]pb12
Also written as [In-111]In-pb12
- Radionuclide
- In-111 t½ 4031.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 2
What it is
- Compound class
- DOTA-conjugated neuropeptide-Y (NPY) analogue peptide
- Target / mechanism
- Human Y1 receptor (hY1R), a G protein-coupled receptor overexpressed on cancer cells PMID 32124111
- Clinical application
- Breast cancer (MCF-7 xenograft model, targeted radionuclide therapy proof-of-concept) PMID 32124111
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | 92 | DOTA-peptide (pb12) | 32124111 2020 EJNMMI Res radiolabeling with 111In, 111InCl3 (Curium Netherlands B.V, ~ 250 MBq) was incubated at room temperature with 50 μg of DOTA-peptide (pb12 or pb13) in 500 μL of 0.1 M acetate buffer (pH 5) for 1.5 h under gentle agitation. |
| Manual synthesis n/a | — | — | — | — | 18B7 | 17875799 2007 Clin Cancer Res 111In-labeled 18B7 and its F(ab')2 and Fab fragments |
Need this precursor?We can point you to suppliers for [111In]pb12, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 32124111. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 32124111: 'DOTA-peptide (pb12 or pb13)'. Stage set/updated at stage 39 from PMID 32124111: 'In this proof-of-concept study, labeling was performed with either native terbium-159 (natTb), as surrogate for 161Tb, or with indium-111 (111In).'.